文献速递类风湿关节炎脊柱关节炎其他结缔组织病

生物制剂和靶向合成改善病情抗风湿药新使用者中神经炎症性疾病的风险

Risk of Neuroinflammatory Diseases Among New Recipients of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2024-05-02

这项基于美国电子健康记录数据库的新使用者比较效果队列研究,纳入类风湿关节炎、银屑病、银屑病关节炎、强直性脊柱炎、克罗恩病或溃疡性结肠炎患者,比较起始TNF抑制剂(n=93,661)与其他b/tsDMARD(n=38,354)后3年内神经炎症不良事件的未调整发生率。TNF抑制剂组神经炎症事件未调整发生率为1.34/1000人年,低于非TNF联合组(1.69/1000人年);总体及每个疾病组内TNF暴露与神经炎症事件均无显著关联(HR 1.01,95%CI 0.75-1.36)。作者认为TNF抑制剂与其他b/tsDMARD新使用者的总体神经炎症事件风险无实质性差异,但该结果可能受通道偏倚影响,应开展随机试验的Meta分析加以验证。

要点

  • TNF抑制剂组神经炎症事件未调整发生率为1.34/1000人年,非TNF联合组为1.69/1000人年,数值上较低。
  • TNF暴露与神经炎症事件总体无显著关联(HR 1.01,95%CI 0.75-1.36),各疾病组内亦无显著关联。
  • 作者认为总体风险无实质性差异,但结果可能受通道偏倚影响,需随机试验Meta分析验证。

核心结论

  • TNF抑制剂新使用者与其他b/tsDMARD新使用者的总体神经炎症事件风险无实质性差异。
  • 作者建议开展随机试验的Meta分析以验证这些发现,并指出结果可能受通道偏倚影响。

研究设计与样本

  • 新使用者比较效果队列研究,使用美国大型电子健康记录数据库。
  • 纳入类风湿关节炎、银屑病、银屑病关节炎、强直性脊柱炎、克罗恩病或溃疡性结肠炎患者,起始TNF抑制剂者n=93,661,起始其他b/tsDMARD者n=38,354,共132,015例。
  • 描述3年期间神经炎症不良事件的未调整发生率。

主要发现

  • 最常见的首个生物制剂为TNF抑制剂。
  • TNF抑制剂新使用者神经炎症事件未调整发生率为1.34/1000人年,低于非TNF联合组的1.69/1000人年。
  • TNF暴露与神经炎症事件总体无显著关联(HR 1.01,95%CI 0.75-1.36)。
  • 各疾病组内TNF暴露与神经炎症事件亦无显著关联。

关键数值与推荐

  • TNF抑制剂组神经炎症事件未调整发生率1.34/1000人年,非TNF联合组1.69/1000人年。
  • TNF暴露与神经炎症事件的HR为1.01(95%CI 0.75-1.36)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出这些发现可能受通道偏倚影响。
  • 作者建议开展随机试验的Meta分析以验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Neuroinflammatory adverse events have been observed among new users of tumor necrosis factor (TNF) inhibitors. No studies to date have compared the real-world risk of TNFs with other new users of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). The objective of this study is to describe the risk of neuroinflammatory disease after initiation b/tsDMARDs. METHODS: This new user comparative effectiveness cohort study used a large US-based electronic health records database to describe the unadjusted incidence of neuroinflammatory adverse events over a 3-year period. The cohort included patients with rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, or ulcerative colitis initiating treatment with a TNF inhibitor (n = 93,661) or other b/tsDMARD (n = 38,354). RESULTS: Among 132,015 patients included in the analysis, the most common first biologic agent was a TNF inhibitor; the unadjusted incidence of neuroinflammatory events was numerically lower among new users of TNF inhibitors (incidence 1.34 per 1,000 patient-years) as compared with the combined non-TNF group (1.69 per 1,000 patient-years). There was no significant association between TNF exposure and neuroinflammatory events as compared with the combined non-TNF b/tsDMARDs overall (hazard ratio 1.01; 95% confidence interval 0.75-1.36) and within each disease group. CONCLUSION: The overall risk of neuroinflammatory events among new users of TNF inhibitors did not differ substantially as compared with new users of other b/tsDMARDs. Meta-analyses of randomized trials should be conducted to corroborate these findings, which may be affected by channeling bias.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Casey M, Pannu S, Bajwa S, et al. Risk of Neuroinflammatory Diseases Among New Recipients of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs. Arthritis Care Res (Hoboken). 2024. PMID: 38570894. doi:10.1002/acr.25340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。